Future treatment of bone metastases

Clinical Cancer Research

Volumn 12, Issue 20 PART 2, 2006, Pages

  Lipton, Allan ^a,b   Berenson, ^c   Roodman, ^c   Clohisy, ^c   Guise, ^c   Coleman, ^c   Boyce, ^c   Body, ^c   Smith, ^c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CATHEPSIN K; CYTOKINE; ENDOTHELIN 1; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NITROGEN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE;

BONE LESION; BONE METASTASIS; CELL DIFFERENTIATION; HUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLINICAL TRIALS; ENDOTHELIN-1; HUMANS; OSTEOCLASTS; OSTEOLYSIS;

EID: 33750720949     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1157     Document Type: Review

References (26)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
2. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
3. Rosen LS, Gordon D, Tchekmedyiann NS, et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized phase 3, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21.
4. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997;80:1572-80.
5. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 2004;31:24-9.
6. Burgess TL, Qian TL, Kaufman S, et al. Osteoprotegerin ligand (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
7. Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
8. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8.
9. Lipton A, Alvarado C, De Boer R, et al. Randomized, active-controlled study of denosumab (AMG162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosponates [abstract]. ASCO 2006 #512.
10. Gelb BD, Shi GP, Champan HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 2006;273:1236-8.
11. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in degradation but not demineralization. J Bone Miner Res 1999;14:1654-63.
12. Votta BJ, Levy MA, Badger A, et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption in vitro and in vivo. J Bone Miner Res 1997;12:1396-406.
13. Stroup GB, Lark M, Veber DF, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001;16:1739-46.
14. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999;24:437-9.
15. Shakespeare W, Yang M, Bohacek R, et al. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A 2000;97:9373-8.
16. Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279:1453-61.
17. Bradbeer JN, Stroup GB, Hoffman SJ. An orally active inhibitor of cytokine synthesis prevents bone loss in the ovariectomized rat [abstract]. J Bone Miner Res 1996;11:1196.
18. Barille-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program 2003;1:248-78.
19. Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65:6282-93.
20. Peles S, Fisher F, Gao M, et al. A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma. [abstract] ASCO 2006 #7548.
21. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997;99:2284-92.
22. Lark MW, Stroup GB, Dodde RA, et al. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J Bone Miner Res 2001;16:319-27.
23. Van der Plujm G, Sijmons B, Vloedgraves H, et al. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001;1:1077-91.
24. Sasaki A, Alcade RE, Nishiyama A, et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998;58:462-7.
25. Guise TA, Grubbs GB, Cui Y, et al. Endothelin A receptor blockade inhibits osteoblastic metastases [abstract]. Proc Am Soc Clin Oncol 2001.
26. Nelson JB, Carducci MA, Padley RJ, et al. The endothelin-A receptor antagonist atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced hormone refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 2001.